ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

Inclusion Criteria Patients must meet the following inclusion criteria during screening: * Age greater than or equal to 18 years. * Both males and females are eligible. All patients should be advised that there are no data on the possible reproductive (teratological) effects of ISIS 14803. Therefore: * a) Females may participate if they are surgically sterile or post-menopausal. Pre-menopausal women may participate if they are abstinent or are compliant with a contraceptive regimen. Abstinence or contraceptive regimen must be maintained during the treatment period and for 4 weeks after discontinuation of therapy. A negative serum pregnancy test (i.e., human chorionic gonadotropin, hCG) within 2 weeks prior to dosing with ISIS 14803 is required for pre-menopausal women. Subjects must not be breast feeding. * b) Male patients must be surgically sterile, abstinent, or utilizing a barrier contraceptive method. Abstinence or contraceptive regimen must be maintained during the treatment period and for 4 weeks after discontinuation of therapy. * Anti-HCV antibody positive. * Plasma HCV RNA greater than 10,000 copies/mL. * Prior liver biopsy indicating chronic hepatitis. * WBC count less than or equal to upper limit of normal. * Absolute neutrophil count in normal range for the laboratory. * Platelet count greater than 130,000 cells/mm³. * Hemoglobin concentration greater than or equal to 11 g/dL. * PT in the normal range for the laboratory. * Normal aPTT. * Bilirubin in the normal range unless due to documented Gilbert's disease. * Serum creatinine less than or equal to 1.5 times the upper limit of the normal range. * Urinalysis showing no evidence of infection or active renal disease (e.g., proteinuria). * Subjects must be able to adhere to the visit schedule set forth in this protocol. * Written informed consent prior to the performance of any study related procedures. Exclusion Criteria: Patients with any of the following criteria during screening will not be eligible: * Human immunodeficiency virus (HIV) infection (Western immunoblot confirmed presence of anti-HIV antibodies or detection of HIV RNA in blood). * Chronic hepatitis B virus (HBV) infection (HBV surface antigen or DNA in blood). * Antiviral therapy for HCV within 3 months. * Immunomodulatory therapy (e.g., systemic corticosteriods or interferon) within 3 months. * Advanced or decompensated liver disease (e.g., history of bleeding varices, spontaneous hepatic encephalopathy, ascites) of any etiology such as alcohol, drug, obesity, or hemochromatosis. * ALT greater than 5x ULN. * Histologic evidence of cirrhosis. * Presence of an underlying disease state associated with active bleeding. * Undergoing therapeutic anticoagulation with heparin or warfarin. * Presence of any other active infection requiring therapy. * Presence of malignancy. * Presence or history of any significant medical illness that might interfere with this study. * Receipt of an investigational new drug, biological or therapeutic device within 30 days of study entry. * Alcohol or drug abuse requiring medical intervention within 2 years. * History of non-compliance with prescribed medical care. * Limited mental capacity or language skills to the extent simple instructions cannot be followed or information regarding adverse events cannot be provided